Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO)
2024-512730-15-00Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Belimumab + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: SLE Responder Index (SRI) response rate at Week 52. Started Jun 2024; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-512730-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512730-15-00.